FINAL SCIENTIFIC PROGRAM -...

LALCA 2016 FINAL SCIENTIFIC PROGRAM 7TH LATIN AMERICAN CONFERENCE ON LUNG CANCER WWW.IASLC.ORG

1

WWW.IASLC.ORG

7th LATIN AMERICAN

CONFERENCE ON LUNG CANCER

FINAL SCIENTIFIC PROGRAM

BECOME A MEMBER OF IASLC | SEE INSIDE COVER FOR MORE INFORMATION

· Collaboration with a global team of thoracic oncology experts and leaders

· Member access to the Journal of Thoracic Oncology, the premier journal in lung cancer, as well as the latest classification and staging publications · Multidisciplinary education including latest in ground-breaking research and treatment of thoracic malignancies

· Discounted registration to IASLC meetings, including the World Conference on Lung Cancer, workshops and webinars

· Eligibility for Fellowship and Travel Awards

· Opportunities to participate in IASLC leadership groups, which influence treatment of lung cancer and other thoracic malignancies world-wide

· Monthly Newsletter and key updates on events, grants and opportunities for members

· Coon

· MeOnaspupu

Full Membership is only $50.00 for Latin American members

Participante da América Latina: Torne-se um sócio pleno por apenas USD 50.00

Participante de America Latina conviertase en Miembro del IASLC por $50.00


3

GRAGRAM 7THTH

CONFERENCE SECRETARIAT

International Conference Services Ltd. (ICS) Suite 300–1201 West Pender Street Vancouver, BC, Canada V6E 2V2 Phone +1 604 681 2153 Fax +1 604 681 1049 www.icsevents.com

CONFERENCE SPONSORS

The 7th Latin American Conference on Lung Cancer would like to thank the following organizations for their generous support.

WE WOULD LIKE TO THANK THE FOLLOWING ORGANIZATIONS

FOR PROVIDING AN EDUCATIONAL GRANT:

GOLD LEVEL

SILVER LEVEL

BRONZE LEVEL

SUPPORTER LEVEL

Table of Contents

welcome message 4

international association for 5 the study of lung cancer (iaslc)

conference committees 5

Local Organizing Committee

International Scientific Committee

general conference information 6

Conference Venue 6 incl. Floor Plans Conference Registration 7 Networking Events 7 Information for Speakers 8 and Abstract Presenters Press & Media 9 Onsite Services and 9 General Information

exhibit information 10 Exhibit Hours, Location 10 and Events Exhibit Floor Plan 11 Exhibitor Listings 12 and Descriptions

lalca 2016 travel awards 13

scientific program 14 Program at a Glance 14 Wednesday, August 24, 2016 16 Thursday, August 25, 2016 17 Friday, August 26, 2016 19 Saturday, August 27, 2016 21 Poster Presentations Friday, August 26, 2016 24 Saturday, August 27, 2016 26

panama information 28

tours 29

abstract author index 30

WWW.IASLC.ORG LALCA 2016 FINAL SCIENTIFIC PROGRAM 7TH LATIN AMERICAN CONFERENCE ON LUNG CANCER

4

GRAGRAM 7THTH

On behalf of the International Association for the Study of Lung

Cancer (IASLC) and the Local Organizing Committee, we are very

pleased to welcome you to the 7th Latin American Conference

on Lung Cancer (LALCA 2016) here in Panama City, Republic of

Panama. More than 500 participants from Latin America and around

the world will join us for this unique and very important scientific

meeting over the next few days.

Lung Cancer is still the leading cause of death not only in Latin America but worldwide. Building on the success of the previous Conferences in Peru (2014), Brazil (2012), Argentina (2010), and Chile (2008), international and national speakers will discuss the science and advances in the treatment and prevention of lung cancer and thoracic malignancies worldwide and Latin America in particular.

simultaneous translation english >< spanish will be provided for all sessions.

With tobacco being the leading cause of morbid-mortality worldwide, the Conference will once again host a Tobacco Control Forum, scheduled for Thursday, August 25. The inaugural ‘Meet the Patient’ Session will take place on Thursday, August 25 as well and will include presentations from scientists, patients and advocates.

This year, for the first time at LALCA, we will host the IASLC School of Thoracic Oncology, an intense workshop for young researchers and clinicians as well as trainee physicians from different disciplines including medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology and pathology. The workshop will take place on Wednesday, August 24 from 08:00-16:00. We will also continue with the very successful Round Table Discussions providing delegates a very unique opportunity to talk and discuss directly with international leaders and local experts on specific topics. A total of 10 different round table topics will be offered. Don’t miss this great opportunity and make sure to participate in the Round Table Discussions on Saturday, August 27.

We also would like to highlight the various symposia hosted by our industry sponsors. They are free of charge to all delegates and the presented topics will compliment the scientific sessions of the Conference.

We also encourage you to visit our exhibitors and poster presenters in the exhibit hall. Poster presenters will be available during the morning and afternoon networking breaks to discuss their research work with you. Please note that a different set of posters will be displayed each day.

We are thrilled that you are joining us for a stimulating and exciting conference and hope you have the chance to take a little extra time to enjoy Panama City, the most cosmopolitan capital in Central America. A center of international banking and trade, the sultry skyline of shimmering glass and steel towers is magnificent. In contrast, the old Panamanian city built by the Spanish known as “Casco Viejo” has become a thriving colonial neighborhood where cobblestones link boutique hotels with underground bars and crumbled ruins with pirate lore.

If you need some extra time to relax after a surely busy conference program, escape is never far. Day trip to sandy beaches, admire the famous Panama Canal, or explore lush rainforests of howler monkeys, toucans and sloths. For those who love fishing, Panama provides plenty of opportunities to do so, both in the Atlantic as well as the Pacific Ocean, which can be reached from Panama City in only a few hours.

Welcome to LALCA 2016! Welcome to Panama City!

Edgardo S. Santos

Roberto Ivan Lopez

Welcome Message

WE

LCO

ME

ME

SS

AG

E


5

GRAGRAM 7THTH

INTERNATIONAL SCIENTIFIC COMMITTEE

international chair european chair Edgardo S. Santos, USA Christian Rolfo, Belgium

members Rosa Acosta, Dominican RepublicOscar Arrieta, MexicoJoao Baptista, Costa RicaCarlos Barrios, BrazilSantiago Bella, ArgentinaEva Bustamantes, ChileAndres Cardona, ColombiaHugo Castro, GuatemalaEduardo Cazap, ArgentinaLuis Corrales-Rodriguez, Costa RicaMauricio Cuello, UruguayLissette Cunillera, Dominican RepublicJesus Davila, VenezuelaJaime De La Garza, MexicoLucia Delgado, UruguayFlora Duarte, HondurasMarileila Garcia, USAHenry Gomez, PeruGlen Goss, CanadaFred R. Hirsch, USADiego Kaen, ArgentinaMelissa Juárez, Costa Rica

LOCAL ORGANIZING COMMITTEE

chair Roberto Ivan Lopez, Panama

members Erick Arauz, PanamaCarlomagno Castillero, PanamaAlejandro Crismatt, PanamaMaria Lim, PanamaRafael Paredes, PanamaTarciso Perea, PanamaGaspar Perez Jimenez, PanamaHector Tapia, PanamaIgnacio Veliz, PanamaRuth Vergara, Panama

Gilberto Lopes, BrazilLuis Mas Lopez, PeruClaudio Martin, ArgentinaClarissa Mathias, BrazilHomero Matos, Dominican RepublicAna Morales, Costa RicaHéroes Morales, GuatemalaRene Munoz, EcuadorGeorge Oblitas, VenezuelaLuis Paz-Ares, SpainNorma Pilnik, ArgentinaIrene Quesada, Costa RicaLuis E. Raez, USASuresh Ramalingam, USAEduardo Richardet, ArgentinaRoberto Salinas, El SalvadorCarlos Vallejos, PeruMario Varangot, UruguayTatiana Vidaurre-Rojas, PeruIgnacio Wistuba, USANise Yamaguchi, Brazil

IAS

LC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes nearly 5,000 lung cancer specialists in 90 countries.

International Association for the Study of Lung Cancer

13100 East Colfax Avenue, Unit 10Aurora, Colorado, USA 80011Phone: +1 855 GO IASLC (+1 855 464 2752) www.iaslc.org

Conference Committees

6

WWW.IASLC.ORG LALCA 2016 FINAL SCIENTIFIC PROGRAM 7TH LATIN AMERICAN CONFERENCE ON LUNG CANCERGRAGRAM 7THTH

CONFERENCE VENUE

The 7th Latin American Conference on Lung Cancer (LALCA 2016) is being held at the Hotel Riu Plaza Panama. All Session Rooms (Panama 1 & 2), the Exhibit Hall (Panama 3 & 4) as well as Registration (Panama Foyer) are located on the 4th floor of the Riu Hotel. The Round Table Discussions on Saturday, August 27 will take place in Room Berlin on the 2nd floor.

Calle 50 con 53 este Urb. Marbella, Ciudad de Panamá, Panamá Tel: (507) 378 9000

FLOOR PLANS

GE

NE

RA

L C

ON

FER

EN

CE

INFO

RM

AT

ION

2ND FLOOR

4TH FLOOR

BERLIN 1+2

ROUND TABLE

DISCUSSIONS

PANAMA 1

SESSION

ROOM

REGISTRATION

SPEAKER PREVIEW CENTER

PANAMA 2

SESSION

ROOM

PANAMA 3+4

EXHIBIT AND

POSTER HALL

General Conference Information

7

LALCA 2016 FINAL SCIENTIFIC PROGRAM 7TH LATIN AMERICAN CONFERENCE ON LUNG CANCER WWW.IASLC.ORG GRAGRAM 7THTH

CONFERENCE REGISTRATION

The Registration Desk is located in the foyer area on the 4th floor of the Riu Hotel.

Registration Desk Hours

THURSDAY, AUGUST 25 09:00 – 20:00

FRIDAY, AUGUST 26 07:30 – 17:00

SATURDAY, AUGUST 27 07:30 – 15:15

Name Badges Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition. A 50 USD fee applies for any name badge reprints due to lost name badges.

Certificate of Attendance Delegates can download their ‘Certificate of Attendance’ after completing the online Conference evaluation form available via the conference website http://lalca2016.iaslc.org/ as of Saturday, August 27.

NETWORKING EVENTS

Welcome Reception


Riu Hotel, Exhibit Hall, Panama 3 + 4, 4th Floor

Faculty Dinner

FRIDAY, AUGUST 26 20:30 – 23:00

By invitation only, please check for your invitation in your registration kit.

Networking Breaks (Snacks and Refreshments provided) FRIDAY, AUGUST 26 10:30 – 11:00

& 16:00 – 16:30


& 16:15 – 16:45

Riu Hotel, Exhibit Hall, Panama 3 + 4, 4th Floor

GE

NE

RA

L C

ON

FER

EN

CE

INFO

RM

AT

ION

8


Poster Session

Friday, August 26

POSTER SET UP TIME: 09:00 – 10:30

POSTER TAKE DOWN TIME: 16:30 – 18:00

POSTER DISPLAY TIME: 10:30 – 16:30

AUTHOR STAND BY TIME: 10:30 – 11:00

& 16:00 – 16:30

(NETWORKING BREAKS)

Topics for Poster Session 1

Prevention, Early Detection, Epidemiology and Tobacco Control

Early Stage NSCLC (Stage I - III)

Advanced NSCLC

Poster Session

Saturday, August 27

POSTER SET UP TIME: 09:00 – 10:30

POSTER TAKE DOWN TIME: 16:45 – 18:00

POSTER DISPLAY TIME: 10:30 – 16:45

AUTHOR STAND BY TIME: 10:30 – 11:00

& 16:15 – 16:45

(NETWORKING BREAKS)

Topics for Poster Session 2

SCLC, Mesothelioma, Thymoma

Biology and Pathogenesis

Pathology

Bronchoscopy

Supportive Care and Others

Immunotherapy

GE

NE

RA

L C

ON

FER

EN

CE

INFO

RM

AT

ION

English and Spanish speaking support will be available to poster presenters. Poster boards are white aluminum. Adhesive tape to set up your poster will be provided.

INFORMATION FOR SPEAKERS AND PRESENTERS

Invited Speakers and Oral Presenters

All speakers are asked to be in the session room at least 15 minutes prior to the start of their session.

Please provide your presentation slides to the Speaker Preview Center, in the foyer on the 4th Floor, at least two (2) hours prior to your presentation. The use of personal laptops for presentations is not allowed as it can cause technical delays and cut into a presenter’s time.

Speaker Preview Center Hours

THURSDAY, AUG. 25 09:00 – 20:00

FRIDAY, AUG. 26 07:30 – 17:00

SATURDAY, AUG. 27 07:30 – 17:00

Poster Presenters

All Poster Presentations/ Boards are located in the Exhibit Hall (Panama 3 + 4) on the 4th floor of the Riu Hotel.

Each Poster Board is identified with a Poster Number that corresponds with the pre-assigned Poster Number published on the Conference website, in this Program Book as well as in the Abstract Book.

Different sets of posters will be displayed each day. Each poster presentation will be on display for the entire day with an author stand-by-time during each day’s morning and afternoon Networking Break. Poster presenters are required to stand by their poster during both times to answer questions from delegates.

9


GE

NE

RA

L C

ON

FER

EN

CE

INFO

RM

AT

ION

ONSITE SERVICES AND GENERAL INFORMATION

Abstract Book

All accepted abstracts will be available online on the Journal of Thoracic Oncology website following the Conference. Each delegate will also receive a printed abstract book with their registration materials.

Certificate of Attendance

Delegates can download their ‘Certificate of Attendance’ after completing the online Conference evaluation form available via the conference website http://lalca2016.iaslc.org/ as of Saturday, August 27.

Networking Breaks

During the Conference days, refreshments will be available in the Exhibit Hall, Panama 3 + 4, during the scheduled morning and afternoon Networking Breaks.

Conference Evaluation

An online Conference evaluation form will be available on the Conference website as of Saturday, August 27. Please help us to improve the Conference by filling out the survey. Thank you for your support!

Simultaneous Translation

The official Conference Language is English; however, presentations can be given in Spanish and simultaneous English and Spanish translation will be provided for all Scientific Sessions except Industry Supported Symposia (unless otherwise stated in this book). Presentation slides must be in ENGLISH. A personal ID is required to receive a wireless receiver for simultaneous translation.

Lost and Found / Messages

Lost and found items should be returned/claimed at the Registration Desk.

Wifi

Wifi will be provided in the meeting space area. Please check for signs with the access information.

PRESS & MEDIA

Press and Media Access

Pre-registered Press and Media representatives are required to check in at the Registration Desk. Non-registered Press and Media representatives should also proceed to the Registration Desk and need to provide their media/press credentials to receive a Press/Media badge.

Use of LALCA Scientific Program Content

Please be aware that the information and materials displayed and/or presented at all sessions of this meeting are the property of the 7th Latin American Conference on Lung Cancer and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced or distributed without the written permission of the International Association for the Study of Lung Cancer. Use of the LALCA/IASLC name and/or logo in any fashion by any commercial entity for any purpose is expressly prohibited without the written permission of the International Association for the Study of Lung Cancer.

10

WWW.IASLC.ORG LALCA 2016 FINAL SCIENTIFIC PROGRAM 7TH LATIN AMERICAN CONFERENCE ON LUNG CANCERGRAGRAM 7

10

LUNG C LATIN AMERICAN CONFEM 7THTH LUNG CANCER

10

EXHIBIT LOCATION

The LALCA 2016 Exhibition is held in Panama 3 + 4 located on the 4th floor of the Riu Hotel.

Exhibit Hours


(WELCOME RECEPTION)

FRIDAY, AUGUST 26 10:30 – 17:00


EXHIBIT EVENTS & HIGHLIGHTS

Welcome Reception Thursday, August 25, 19:00 – 20:30

Inclusive with full conference registration. Additional tickets for friends and guests are available at 50 USD and can be purchased at the registration desk.

Exhibits are an integral part of the experience at LALCA 2016. The Exhibition opens on Thursday, August 25 at 19:00 with the Welcome Reception. Enjoy local wines and hors d’oeuvres, allowing you the opportunity to mix and mingle with exhibitors, colleagues and friends.

Networking Breaks Friday, August 26 10:30 – 11:00 & 16:00 – 16:30

Saturday, August 27 10:30 – 11:00 & 16:15 – 16:45

On Friday, August 26 and Saturday, August 27, refreshments are available for registered delegates in the Exhibit Hall during the morning and afternoon Networking Breaks.

Poster Sessions

The Poster Sessions are an important educational part of this meeting. All poster presentations are located in the Exhibit Hall. All poster presentations have been assigned a consecutive publication number for locating the abstract/poster in this Program Book and the Abstract Book which corresponds to the Poster Board Numbers.

For further details regarding Poster display and author stand by times, please refer to page 8 in this program book.

Exhibit Information

EX

HIB

IT I

NFO

RM

AT

ION

11


EX

HIB

IT I

NFO

RM

AT

ION

EXHIBITION FLOOR PLAN

PANAMA 3 + 4

RENCE ON PROGRA LATIN AMERICANGRAGRAM 7THTH CE ON LUNG CANCER ANCER WWWER WWW.IASLC.ORG

12

WWW.IASLC.ORG LALCA 2016 FINAL SCIENTIFIC PROGRAM 7TH LATIN AMERICAN CONFERENCE ON LUNG CANCERGRAGRAM 7

12

LUNG C LATIN AMERICAN CONFEM 7THTH LUNG CANCER

12

Guardant Health is focused on developing breakthrough diagnostics that can transform cancer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.

The Denver-based International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 5,000 lung cancer specialists in 90 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high quality medicines that meet real needs, and today we remain true to that mission in all our work.

For 125 years, MSD has been a global health care leader working to help the world be well. Through our medicines, vaccines and biologic therapies, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.

OncoDNA, The Cancer Theranostic Company, is the European leading oncology company providing solutions for cancer treatments, at the same time contributing to the knowledge applied to the fight against cancer. OncoDNA’s team is fully dedicated to help oncologists worldwide developing services to enable better treatment choices and treatment efficacy monitoring. The innovative approach of OncoDNA is based on its unique OncoDEEP-OncoTRACE combination.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

EX

HIB

IT I

NFO

RM

AT

ION

EXHIBITOR COMPANY DESCRIPTIONS

13


LA

LCA

20

16 T

RA

VE

L A

WA

RD

S

Congratulations to the following LALCA 2016 Travel Award Winners!

Award Winners will be presented with their awards during the Closing Ceremony on Saturday, August 27, 2016 from 18:00 – 18:45.

Paola De La Iglesia, Argentina

PD1.04 (also presented as P2.19): Infrequent Staining Patterns in ALK Immunohistochemistry: Correlation with Fish Analisys

Poster Discussion Session 1, Saturday, August 27

Stéfano Ciriglliano, Argentina

P2.05: The Synthetic Peptide CIGB-300 Inhibits NF-κB Translocation Affecting the Survival and Chemoresistance of NSCLC Cell Lines

Poster Session 2, Saturday, August 27

Maurenis Hernandez, Cuba

P2.40: CIMAvaxEGF Vaccine for the Treatment of Real-World NSCLC Patients

Poster Session 2, Saturday, August 27

Wilson Ezequiel Neto, Brazil

P1.06: Lung Nodule Volumetry: Analysis of the Measurement Variation

Poster Session 1, Friday, August 26

Luiza Weis, Brazil

P1.36: Non-Small-Cell Lung Cancer and Brain Metastases in Brazil

Poster Session 1, Friday, August 26

LALCA 2016 Travel Awards

14


PR

OG

RA

M A

T A

GL

AN

CE

THURSDAY AY AUGUST 25, 2016

PANAMA 1AMSTERDAM, 2ND FLOOR PANAMA 2

Opening Ceremony

(12:00 – 13:00)

Cancer Control Program and Tobacco Forum

(13:00 – 14:00)

Symposium Supported by AstraZeneca

(18:00 – 19:00)

Patient Advocacy Session

(10:15 – 11:30)

Young Investigator’s Session

(16:45 – 17:45)

Diagnostic Imaging Innovations

(16:45 – 17:45)

Lung Cancer Screening

(15:30 – 16:30)

Symposium Supported by MSD

(18:00 – 19:00)

Symposium Supported by Caris

(14:15 – 15:15)

Symposium Supported by Varian

(14:15 – 15:15)

Welcome Reception

Official Opening of the Exhibit Hall (19:00 – 20:30)

REGISTRATION OPEN 09:00–20:00

SPEAKER PREVIEW CENTER OPEN 09:00–20:00

WEDNESDAY DAY AUGUST 24, 2016

07:00

07:30

08:00

08:30

09:00

09:30

10:00

10:30

11:00

11:30

12:00

12:30

13:00

13:30

14:00

14:30

15:00

15:30

16:00

16:30

17:00

17:30

18:00

18:30

19:00

19:30

20:00

20:30

21:00

21:30

22:00

22:30

23:00

IASLC School of Thoracic Oncology [Ticketed Event - Breakfast and Lunch Provided]

(07:30 – 16:00)

Program at a Glance

15


PR

OG

RA

M A

T A

GL

AN

CE

FRIDAY AY AUGUST 26, 2016

PANAMA 1 PANAMA 2

IASLC Business Meeting Location: London, 2nd Floor

[by invitation only]

(07:00 – 08:00)

GENERAL SESSION 1: Innovative Clinical Trial Designs

for NSCLC

(09:30 – 10:30)

GENERAL SESSION 2: Lung Cancer Pathology in the Era

of Targeted Therapy

(11:00 – 12:00)

GENERAL SESSION 3: Diagnostic and Staging Issues in the

Contemporary Pulmonary Medicine

(11:00 – 12:00)

GENERAL SESSION 4: Molecular Markers

in Lung Cancer

(12:15 – 13:15)

GENERAL SESSION 7: Stage IIIA/B Non-Small

Cell Lung Cancer

(16:30 – 17:30)

Symposium Supported by Pfizer

(17:45 – 18:45)

GENERAL SESSION 6: Adjuvant Therapy

in the Molecular Era

(14:45 – 16:00)

GENERAL SESSION 5: New Developments

in Surgery

(12:15 – 13:15)

GENERAL SESSION 8: Squamous Cell

Carcinoma

(16:30 – 17:30)

Symposium Supported by Guardant Health

(19:00 – 20:00)

Presidential Symposium Including Top Rated

Abstracts (08:00 – 09:15)

Networking Break and Poster Viewing [Poster Session 1] (10:30 – 11:00)


Symposium Supported by Boehringer Ingelheim

(13:30 – 14:30)

Faculty Dinner (by invitation only)

(20:15 – 23:00)

PO

STER

S O

N D

ISP

LAY

IN T

HE

EX

HIB

IT H

ALL

(1

0:3

0–

17:

00

)

REGISTRATION OPEN 07:30–17:00

SPEAKER PREVIEW CENTER OPEN 07:30–17:00REGISTRATION OPEN 07:30–15:15

SPEAKER PREVIEW CENTER OPEN 07:30–17:00

SATURDAY AY AUGUST 27, 2016

PANAMA 1 PANAMA 2

GENERAL SESSION 9: Management of Advanced Stage

Non Squamous-NSCLC

(09:30 – 10:30)

GENERAL SESSION 10: Immunotherapy in Non-Small

Cell Lung Cancer

(09:30 – 10:30)

GENERAL SESSION 11: Small Cell Lung Cancer &

Neuroendocrine Tumor (NET)

(12:45 – 13:45)

GENERAL SESSION 13: Novel Therapies Targetting Lung

Cancer Pathways

(15:15 – 16:15)

GENERAL SESSION 15: Epidermal Growth Factor Receptor (EGFR)

Mutation as Targeted Therapy

(16:45 – 17:45)

GENERAL SESSION 16: ALK/EML4 Translocation as

Targeted Therapy

(16:45 – 17:45)

Closing Plenary

(18:00 – 18:30)

GENERAL SESSION 12: Advanced Radiation Technology

(12:45 – 13:45)

GENERAL SESSION 14: Mesothelioma, Thymoma,

and Thymic Carcinoma

(15:15 – 16:15)

Poster Discussion Session 1 (08:00 – 09:15)

Poster Discussion Session 2

(08:00 – 09:15)


Roundtable Discussions Berlin 1 + 2, 2nd Floor

(11:00 – 12:30)


Independent Satellite Symposium (14:00 – 15:00)

PO

STER

S O

N D

ISP

LAY

IN T

HE

EX

HIB

IT H

ALL

(1

0:3

0–

17:

00

)

07:00

07:30

08:00

08:30

09:00

09:30

10:00

10:30

11:00

11:30

12:00

12:30

13:00

13:30

14:00

14:30

15:00

15:30

16:00

16:30

17:00

17:30

18:00

18:30

19:00

19:30

20:00

20:30

21:00

21:30

22:00

22:30

23:00

Program listings are subject to change.


16

GRAGRAM 7THTH

WE

DN

ES

DA

Y, A

UG

UST

24

, 20

16

Wednesday, August 24, 2016

07:30 – 16:00

IASLC SCHOOL OF THORACIC ONCOLOGY [TICKETED EVENT: 30 USD REGISTRATION FEE APPLIES]

Location: Amsterdam (2nd Floor) Chairs: Suresh Ramalingam, USA & Luis E. Raez, USA

07:30 Breakfast and Registration

08:15 Welcome and Introductions

08:20 Pre-meeting Test

08:45 Pulmonary Medicine, Robert Keith, USA

09:15 Pathology, Fred R. Hirsch, USA & Marileila Varella-Garcia, USA

09:45 Thoracic Surgery, Harvey Pass, USA

10:15 Break

10:30 Radiation Oncology, Ana Botero, USA

11:00 Medical Oncology, Christian Rolfo, Belgium

11:30 Question and Answers

11:45 Working Lunch

12:00 Biostatistics, Mary Redman, USA

12:45 Workstation 1, Pulmonary, Robert Keith, USA

13:15 Workstation 2, Pathology, Ignacio Wistuba, USA

13:45 Workstation 3, Thoracic Surgery, Harvey Pass, USA

14:15 Break

14:30 Workstation 4, Radiation Oncology, Ana Botero, USA

15:00 Workstation 5, Medical Oncology, Luis E. Raez, USA

15:30 Post-meeting Test

16:00 Wrap up and Adjourn


17

GRAGRAM 7THTH

TH

UR

SD

AY

, AU

GU

ST 2

5, 2

016

Thursday, August 25, 2016

10:15 – 11:30

PATIENT ADVOCACY SESSIONLocation: Panama 1 (4th Floor) Chair: Nise Yamaguchi, Brazil

10:15 Welcome, Nise Yamaguchi, Brazil

10:20 Tumor Molecular Profile: A New Challenge, Christian Rolfo, Belgium

10:30 Learning from Patients: The Story of..., Carolina Santamaria, Panama

10:40 Our Body Helping to Cure Cancer: Immunotherapy, Roberto Lopez, Panama

10:50 Celebrating the Survivors: The Story of..., Veronica Hughes, Brazil

11:00 Is It Easy to Get New Drugs in Latin America?, Nise Yamaguchi, Brazil

11:10 Open Discussion Moderated by: Christian Rolfo, Belgium

11:20 Closing Remarks, Nise Yamaguchi, Brazil

12:00 – 13:00

OPENING CEREMONYLocation: Panama 1 (4th Floor) Chairs: Roberto I. Lopez, Panama & Edgardo S. Santos, USA

Welcome and Introduction to LALCA 2016, Edgardo S. Santos, USA

The Future of Lung Cancer Management in Panama, Roberto I. Lopez, Panama

Welcome from IASLC, Fred R. Hirsch, IASLC CEO, USA

13:00 – 14:00

CANCER CONTROL PROGRAM AND TOBACCO FORUMLocation: Panama 1 (4th Floor) Chairs: Nise Yamaguchi, Brazil & Erick Arauz, Panama

13:00 Early Detection in Heavy Smoker, Ricardo Sales do Santos, Brazil

13:15 Importance of Smoking Cessation in the Treatment of Lung Cancer Patient, Carolyn Dresler, USA

13:30 Tobacco Control in Youth, Nise Yamaguchi, Brazil

13:45Panel Discussion, Ricardo Sales do Santos, Brazil, Carolyn Dresler, USA, Nise Yamaguchi, Brazil, Veronica Hughes, Brazil

14:15 – 15:15

CONCURRENT INDUSTRY SUPPORTED SYMPOSIA

PANAMA 1 (4TH FLOOR) PANAMA 2 (4TH FLOOR)

INDUSTRY SYMPOSIUM SUPPORTED BY VARIAN: The Role of Salvage SBRT in Recurrent Lung Cancer after Previous Radiotherapy

INDUSTRY SYMPOSIUM SUPPORTED BY CARIS: Multiplatform Tumor Profiling in Lung Cancer

15:30 – 16:30

LUNG CANCER SCREENINGLocation: Panama 1 (4th Floor) Chairs: Ignacio Gil-Bazo, Spain & Luis Herrera, USA

15:30 Lung Cancer Computer Tomography Screening, Claudia I. Henschke, USA

15:50 Lung Cancer Screening: Impact in Survival and Economics, Luis Corrales-Rodriguez, Costa Rica

16:10 Lung Cancer Screening in Latin America: Challenges and Progress, Carlos Barrios, Brazil

09:00 – 20:00 REGISTRATION DESK OPEN Location: Foyer Area (4th Floor)

09:00 – 20:00 SPEAKER PREVIEW CENTER OPEN Location: Foyer Area (4th Floor)

19:00 – 20:30 EXHIBIT HALL OPEN Location: Panama 3 & 4 (4th Floor)

18


TH

UR

SD

AY

, AU

GU

ST 2

5, 2

016

16:45 – 17:45

CONCURRENT SESSIONS


DIAGNOSTIC IMAGING INNOVATIONS Chairs: Luis Leonardo Rojas, Colombia & Hector Tapia, Panama

YOUNG INVESTIGATOR’S SESSION Chairs: Maria Lim, Panama & Belisario Arango, USA

16:45 PET CT Scan as a Tool for Lung Cancer Management: Utility, Yariela Herrera Malo, Panama

16:45 How to Write a Manuscript and a Research Grant?, Gilberto Lopes, Brazil

17:00 EBUS and Navigation System to Yield a Diagnosis, Jonathan Waxman, USA

17:05 How to Incorporate Research in Panama and Latin America?, Roberto I. Lopez, Panama

17:15 Stereotactic Body Radiotherapy in NSCLC with Oligometastic Disease, Ana Botero, USA

17:25 The Role of Medical School to Promote Basic and Clinical Research: Obstacles, Resources and Policies, Enrique Mendoza, Panama

17:30 Role of Interventional Radiology in the Modern Era of Lung Cancer, Ligia Cardona, Dominican Republic

18:00 – 19:00

CONCURRENT INDUSTRY SUPPORTED SYMPOSIA


INDUSTRY SYMPOSIUM SUPPORTED BY ASTRAZENECA: Advances in Therapy of EGFR-mutated Lung Cancer

INDUSTRY SYMPOSIUM SUPPORTED BY MSD: Immuno-Oncology: A Renaissance in the Treatment of NSCLC

19:00 – 20:30

WELCOME RECEPTION & OFFICIAL OPENING OF THE EXHIBIT HALLLocation: Exhibit Hall, Panama 3 & 4 (4th Floor) - Snacks and refreshments provided

19


FRID

AY

, AU

GU

ST 2

6, 2

016

Friday, August 26, 2016

07:00 – 08:00

IASLC BUSINESS MEETING (BY INVITATION ONLY)Location: London (2nd Floor)

08:00 – 09:15

PRESIDENTIAL SYMPOSIUMLocation: Panama 1 (4th Floor) Chairs: Roberto I. Lopez, Panama, Edgardo S. Santos, USA & David Carbone, USA

08:00O.01 Acquired Resistance to EGFR-TKIs in EGFR-Mutant Lung Adenocarcinoma Among Hispanics(Rbiop-CLICaP), Oscar Arrieta, Mexico

08:15O.02 Plasma Next Generation Sequencing of over 5,000 Advanced Non-Small Cell Lung Cancer Patientswith Clinical Correlations, David R. Gandara, USA

08:30 O.03 Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative toPD-L1 Expression, Gilberto Lopes, Brazil

08:45O.04 Profiling of MET-Amplified Non-Small Cell Lung Cancer (NSCLC), Correlation to cMET Protein Expression/MET Exon 14 Skipping, David Arguello, USA

09:00 Discussant: Roy Herbst, USA

09:30 – 10:30

GENERAL SESSION 1: INNOVATIVE CLINICAL TRIAL DESIGNS FOR NSCLCLocation: Panama 1 (4th Floor) Chairs: Carlos Vallejos, Peru & Robert Pirker, Austria

09:30 Bringing Opportunities in Clinical Research for Latin America, Christian Caglevic, Chile

09:45 Master Protocols, David R. Gandara, USA

10:00 Lung MAP, Roy Herbst, USA

10:15Bringing Research to the Patient: Remote Consenting for a Novel Trial- Genomics of Young Lung Cancer, Barbara Gitlitz, USA

10:30 – 11:00

NETWORKING BREAK AND POSTER VIEWING [Poster Session 1]Location: Exhibit Hall, Panama 3 & 4 (4th Floor) - Snacks and refreshments provided

11:00 – 12:00

CONCURRENT SESSIONS


GENERAL SESSION 2: LUNG CANCER PATHOLOGY IN THE ERA OF TARGETED THERAPYChairs: Marileila Varella-Garcia, USA & Ruth Vergara, Panama

GENERAL SESSION 3: DIAGNOSTIC AND STAGING ISSUES IN THE CONTEMPORARY PULMONARY MEDICINE Chairs: Francisco Tarrazzi, USA & Carlomagno Castillero, Panama

11:00 The Importance of Histologic Diagnosis in Lung Cancer: Clinical Implications, Robert Pirker, Austria

11:00 Assessment of the Pulmonary Nodule, Mark Block, USA

11:15 Tissue Quality Control for Molecular Testing, Ignacio I. Wistuba, USA

11:15 Potential and Limitations of EBUS for Diagnosis and Staging, Francisco Tarrazzi, USA

11:30 Gene Expression Profile for Carcinoma of Unknown Primary, Carlos Barrios, Brazil

11:30 Optimization of Bronchoscopic Samples in the Era of Molecular Pathology, Johan Vansteenkiste, Belgium

11:45 Question and Answer Period 11:45 Roadmap for Liquid Biopsy in Lung Cancer, Christian Rolfo, Belgium



10:30 – 17:00 EXHIBITS OPEN / POSTERS ON DISPLAY Location: Exhibit Hall, Panama 3 & 4 (4th Floor)


20

GRAGRAM 7THTH

FRID

AY

, AU

GU

ST 2

6, 2

016

12:15 – 13:15

CONCURRENT SESSIONS


GENERAL SESSION 4: MOLECULAR MARKERS IN LUNG CANCERChairs: Jaime De La Garza, Mexico & Bruno Bastos, USA

GENERAL SESSION 5: NEW DEVELOPMENTS IN SURGERY Chairs: Mark Block, USA & Rafael Andrade-Alegre, Panama

12:15 Molecular Markers in Lung Adenocarcinomas, Marileila Varella-Garcia, USA

12:15 Invasive Mediastinal Staging: Mediastinoscopy, EBUS and EUS, Jonathan Waxman, USA

12:30 Molecular Markers in Squamous Cell Carcinoma, Luis E. Raez, USA

12:30 VATS, Robot-Assisted or Thoracotomy for Lung Cancer Surgery, Mark Block, USA

12:45 Molecular Diagnosis Guidelines Recommended Internationally, Fred R. Hirsch, USA

12:45 Sublobar Resection for Stage I NSCLC, Harvey Pass, USA

13:00 Molecular Testing in Lung Cancer: Efforts and Perspectives in Latin America, Tatiana Vidaurre-Rojas, Peru

13:00 Endosonography and Navigation System to Secure Tissue Diagnosis, Johan Vansteenkiste, Belgium

13:30 – 14:30

INDUSTRY SYMPOSIUM SUPPORTED BY BOEHRINGER INGELHEIM: Treatment Updates in NSCLC: Translating Evidence into Clinical Practice Location: Panama 1 (4th Floor)

14:45 – 16:00

GENERAL SESSION 6: ADJUVANT THERAPY IN THE MOLECULAR ERALocation: Panama 1 (4th Floor) Chairs: Barbara Gilitz, USA & Clarissa Mathias, Brazil

14:45 Adjuvant Chemotherapy for NSCLC: Where Are We Now?, Norma Pilnik, Argentina

15:00 Role of Targeted Agents in the Adjuvant Setting, Raja Mudad, USA

15:15 Is There a Role for Immunotherapy in Lung Cancer Adjuvant Setting?, Luis Paz-Ares, Spain

15:30 Prognostic and Predictive Makers for Adjuvant Therapy NSCLC, Gilberto Lopes, Brazil

15:45 Question and Answer Period

16:00 – 16:30


16:30 – 17:30

CONCURRENT SESSIONS


GENERAL SESSION 7: STAGE IIIA/B NON-SMALL CELL LUNG CANCER Chairs: Jorge Gomez, USA & Carlos Barrios, Brazil

GENERAL SESSION 8: SQUAMOUS CELL CARCINOMA Chairs: Jhanelle Gray, USA & Alejandro Crissmatt, Panama

16:30 Optimal Radiation Dose and Schedule, Puneeth Iyengar, USA

16:30 Biological Insights of Squamous Cell Carcinoma —Novel Targets, Suresh Ramalingam, USA

16:45 Optimal Combined Modality Therapy for LA-NSCLC, Alberto Chiappori, USA

16:45 Maintenance Therapy in Squamous Cell Carcinoma, Luis Leonardo Rojas, Colombia

17:00 Is There a Role of Neoadjuvant Therapy for N2 Disease, Harvey Pass, USA

17:00 Checkpoint Inhibitors and Vaccine in Squamous Cell Carcinoma, Glenwood Goss, Canada

17:15 Integration of Molecular Imaging and Agents in LA-NSCLC, Johan Vansteenkiste, Belgium

17:15 How to Approach Second-Line in Squamous Cell Carcinoma, David R. Gandara, USA

17:45 – 18:45

INDUSTRY SYMPOSIUM SUPPORTED BY PFIZER: ROS-1: How to Incorporate New Markers into Oncogene Driven Treatments Location: Panama 1 (4th Floor)

19:00 – 20:00

INDUSTRY SYMPOSIUM SUPPORTED BY GUARDANT HEALTH:Clinical Utility of Liquid Biopsies to Determine NCCN Mutation Targets in NSCLC Location: Panama 2 (4th Floor)

20:15 – 23:00

FACULTY DINNERBy invitation only


21

GRAGRAM 7THTH

SA

TU

RD

AY

, AU

GU

ST 2

7, 2

016

Saturday, August 27, 2016

08:00 – 09:15

CONCURRENT SESSIONS


POSTER DISCUSSION SESSION 1 Chairs: Roberto I. Lopez, Panama and Edgardo S. Santos, USA

POSTER DISCUSSION SESSION 2 Chairs: Luis E. Raez, USA & David Carbone, USA

08:00 PD1.01: LCSS as a Marker of Treatment Benefit with Nivolumab vs Docetaxel in Pts with Advanced Non-Squamous NSCLC from CheckMate 057, Richard J. Gralla, USA

08:00 PD2.01: Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar,Luis E. Raez, USA

08:05 PD1.02: The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis, Gilberto Lopes, Brazil

08:05 PD2.02: 08:05 Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients with ALK+ NSCLC,Ticiana Leal, USA

08:10 PD1.03: EGFR Mutation Testing Patterns and Results in Brazil and the Need for Greater Public Health Awareness of Molecular TestingGilberto Lopes, Brazil

08:10 Discussant: Clarissa Mathias, Brazil

08:15 Discussant: Nise Yamaguchi, Brazil 08:25 Question and Answer Period

08:30 Question and Answer Period 08:35 PD2.04: Pem/CBP/Bev Followed by Maintenance Pem/Bev in Hispanic Patients with NSCLC: Outcomes According to TS, ERCC1 and VEGF,Leonardo Rojas, Colombia

08:35 PD1.04: Infrequent Staining Patterns in ALK Immunohistochemistry: Correlation with Fish Analiss, Paola De La Iglesia, Argentina

08:40 PD2.05: Radiosurgery, a New Paradigm in Metastatic Non-Small Cell Lung Cancer (NSCLC) to the Brain: An Update,Beatriz Amendola, USA

08:40 PD1.05: The Genomics of Young Emergent Lung Cancer, Barbara Gitzlitz, USA

08:45 PD2.06: Bayesian Network Meta-Comparison of Maintenance Treatments for Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients,Gilberto Lopes, Brazil

08:45 PD1.06: Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment, Roy Herbst, USA

08:50 Discussant: Antoinette Wozniak, USA

08:50 Discussant: Mercedes Liliana Dalurzo, Argentina 09:05 Question and Answer Period


09:30 – 10:30

CONCURRENT SESSIONS


GENERAL SESSION 9: MANAGEMENT OF ADVANCED STAGE NON SQUAMOUS-NSCLCChairs: Luis Paz-Ares, Spain & Miguel Villalona, USA

GENERAL SESSION 10: IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER Chairs: Ana Oton, USA & Eduardo Richardet, Argentina

09:30 Front Line Therapy for EGFR/ALK/ROS-1 Genomic Aberrations, Luis Paz-Ares, Spain

09:30 Immunotherapy: Making it in a Simple Language, Ada Blidner, Argentina

09:45 How to Deal with ALK Resistance - How Far to Go?, Christian Rolfo, Belgium

09:40 Predictive Assays for Immunotherapy, Fred R. Hirsch, USA

10:00 Selecting Patients for Maintenance Therapy, Giorgio Scagliotti, Italy

09:50 Clinical Trials with Anti-PD-1, Luis E. Raez, USA

10:15 Molecular Targeted Therapy for Brain Metastases and Leptomeningeal Disease, Jorge Gomez, USA

10:00 Clinical Trials with Anti-PDL-1 Inhibitors, Clarissa Mathias, Brazil

10:10 Other Immunotherapy Pathways - CTL4 and Others, David Carbone, USA


10:30 – 11:00




10:30 – 17:00 EXHIBITS OPEN / POSTERS ON DISPLAY Location: Exhibit Hall, Panama 3 & 4 (4th Floor)


22

GRAGRAM 7THTH

SA

TU

RD

AY

, AU

GU

ST 2

7, 2

016

11:00 – 12:30

ROUNDTABLE DISCUSSIONSLocation: Berlin 1 & 2 (2nd Floor) Chairs: Eduardo Richardet, Argentina & Edgardo S. Santos, USA

Novel Approaches in Surgery: Robotic Surgery, VATS, Navigation SystemLuis Herrera, USA & Harvey Pass, USA

Palliative Care in Lung CancerErick Arauz, Panama & Luis Mas Lopez, Peru

Commentator: Luis Ubillos, Uruguay

Treatment of Wild Type Lung Cancer Tumours First and Second LineTatiana Vidaurre-Rojas, Peru & Alejandro Crismatt, Panama

Commentator: Diego Kaen, Argentina

Therapy of Tumours Carrying EGFR Mutations or ALK Translocations Jorge Rios, USA & Maria Pietanza, USA Commentator: Martin E. Richardet, Argentina

How to Study Molecular Biology and Tumour MarkersIgnacio Wistuba, USA & Ruth Vergara, Panama

Commentator: Omar Castillo, Panama

Radiation Therapy in Lung CancerMichael Kasper, USA & Ignacio Castellon, USA

Commentator: Gaspar Perez Jimenez, Panama

New Molecules and Therapies for Lung CancerSuresh Ramalingam, USA & Luis Leonardo Rojas, Colombia Commentator: Martin Dietrich, USA

Diagnosis and Staging in Lung CancerMarileila Varella-Garcia, USA & Cesar Perez, USA

Commentator: Mauricio Cuello, Uruguay

Locally Advanced Non-Small Cell Lung CancerGiorgio Scagliotti, Italy & Jhanelle Gray, USA

Commentator: Luis Corrales-Rodriguez, Costa Rica

Therapy of EGFR/ALK Resistant Lung Cancer TumoursBruno Bastos, USA & Roy Herbst, USA

Commentator: Claudio Martin, Argentina

Management of Toxicities from Immunotherapies in Lung CancerChristian Rolfo, Belgium & Luis Paz-Ares, Spain

Commentator: Belisario Arango, USA

Adjuvant Therapy in Non-Small Cell Lung CancerRaja Mudad, USA & Oscar Arrieta, Mexico

Commentator: Norma Pilnik, Argentina

Management of Limited and Extensive Small Cell Lung CancerEdgardo Santos, USA & Sai-Hong Ou, USA

12:45 – 13:45

CONCURRENT SESSIONS


GENERAL SESSION 11: SMALL CELL LUNG CANCER & NEUROENDOCRINE TUMOR, NET Chairs: Oscar Arrieta, Mexico & Cesar Perez, USA

GENERAL SESSION 12: ADVANCED RADIATION TECHNOLOGY Chairs: Puneeth Iyengar, USA & Ana Botero, USA

12:45 Small Cell Cancer Biology: Are There New Targets?, Maria Pietanza, USA

12:45 Radiation Oncology Challenges in Latin America, Ignacio Castellon, USA

13:00 Systemic Chemotherapy for SCLC, Nise Yamaguchi, Brazil

13:00 Role of SBRT in Early Stage NSCLC, Puneeth Lyengar, USA

13:15 Success and Challenges of Radiation Therapy for SCLC, Ignacio Castellon, USA

13:15 Role of SBRT in Advanced NSCLC, Michael Kasper, USA

13:30 Management of Well-Differentiated NET, Aurelio Castrellon, USA

13:30 Role of Proton in Lung Cancer, Ana Botero, USA

14:00 – 15:00

INDEPENDENT SATELLITE SYMPOSIUM: Individualizing the Treatment of Advanced NSCLCLocation: Panama 1 (4th Floor)


23

GRAGRAM 7THTH

SA

TU

RD

AY

, AU

GU

ST 2

7, 2

016

15:15 – 16:15

CONCURRENT SESSIONS


GENERAL SESSION 13: NOVEL THERAPIES TARGETING LUNG CANCER PATHWAYS Chair: Paul Bunn Jr., USA

GENERAL SESSION 14: MESOTHELIOMA, THYMOMA, AND THYMIC CARCINOMA Chairs: Jorge Rios, USA & Sai-Hong Ou, USA

15:15 RET/BRAF, Antoinette Wozniak, USA

15:15 VATS and Robotic Surgery in Mesothelioma, Francisco Tarrazzi, USA

15:25 MET and MET Exon 14 Skipping, Paul Bunn Jr., USA

15:30 Biological Insights and Novel Therapy for Malignant Mesothelioma, Sai-Hong Ou, USA

15:35 Repair Inhibitors, Miguel Villalona, USA

15:45 Current Standard of Care for the Treatment of Thymoma: What’s New?, Luis Corrales-Rodriguez, Costa Rica

15:45 NF-1, David Carbone, USA

16:00 Emerging Biology and Therapeutics in Thymic Carcinoma, Jorge Gomez, USA

15:55 ROS-1, Ignacio Gil-Bazo, Spain

16:05 Questions and Answer Period

16:15 – 16:45


16:45 – 17:45

CONCURRENT SESSIONS


GENERAL SESSION 15: EPIDERMAL GROWTH FACTOR RECEPTOR, EGFR MUTATION AS TARGETED THERAPY Chairs: Sai-Hong Ou, USA & Manuel Magallanes Maciel, Mexico

GENERAL SESSION 16: ALK/EML4 TRANSLOCATION AS TARGETED THERAPY Chairs: Alfredo Aguilar, Peru & Cesar Perez, USA

16:45 Actual Status of First and Second Generation EGFR TKIs in the Treatment of NSCLC, Fred R. Hirsch, USA

16:45 Crizotinib, Ceritinib and Alectinib, the Approved ALK Inhibitors: Where Are We Now?, Ana Oton, USA

17:00 Targeting T790M in Lung Cancer: Osimertinib and Rociletinib, Suresh Ramalingam, USA

17:00 Novel Molecular Mechanisms of Resistance to ALK Inhibition, Clarissa Mathias, Brazil

17:15 New Insights of EGFR Inhibition: EGF816, ASP8273, and AUY922, Paul Bunn Jr., USA

17:15 ALK Inhibitors with Central Nervous System Penetration for Management of Lung Cancers, Jhanelle Gray, USA

17:30 EGFR TKIs with Central Nervous System Penetration for Management of Lung Cancers, Sai-Hong Ou, USA

17:30 ALK Inhibitors in Combination with other Targeted Therapies and Radiotherapy in Patients with ALK+ NSCLC, Luis Ubillos, Uruguay

18:00 – 18:30

CLOSING CEREMONYLocation: Panama 1 (4th Floor) Chairs: Roberto I. Lopez, Panama & Edgardo S. Santos, USA

Award Presentations, Roberto Lopez, Panama

Closing Remarks, Edgardo S. Santos, USA & Fred R. Hirsch, USA

Invitation to LALCA 2018


24

GRAGRAM 7THTH

PO

STE

R S

ES

SIO

N 1

| F

RID

AY

, AU

GU

ST 2

6, 2

016

prevention, early detection, epidemiology and tobacco control

P1.01: Herbal Medicine Today: Clinical and Research Issues Taqee Ansari Mohammed, India

P1.02: Lung Cancer - a Previously Years Survival Study. First Statistical Evidence at National Institute of Oncology in Paraguay Silvia Ayala Leon, Paraguay

P1.03: Utility of a Combined Panel of Six Serum Tumor Markers for Lung Cancer Rafael Molina, Spain

P1.04: Defining the Genetic Architecture of Lung Cancer Etiology Christopher Amos, USA

P1.05: An International Epidemiological Analysis of Young Patients Diagnosed with NSCLC (AduJov-CLICaP) Luis Corrales-Rodriguez, Costa Rica

P1.06: Lung Nodule Volumetry: Analysis of the Measurement Variation Wilson Ezequiel Neto, Brazil

P1.07: University Students’ Perceptions about Effectiveness of MPOWER Policies on Tobacco Control Omar Castillo-Fernandez, Panama

P1.08: Updated Analysis of Global Epidemiology of EGFR Mutation in Advanced Non-Small Cell Lung Cancer Gilberto Lopes, Brazil

P1.09: Delays in the Diagnosis and Treatment of Lung Cancer Martin Richardet, Argentina

P1.10: Follow-Up on Results of a Multidisciplinary Team in the Management of Non-Small Cell Lung Cancer in a Developing Country Luis Corrales-Rodriguez, Costa Rica

P1.11: Surveillance System of Tabaquism in Cuba 1995-2014 and Early Detection in Heavy Smokers Patricia Varona Perez, Cuba

P1.12 (also presented as PD1.03): EGFR Mutation Testing Patterns and Results in Brazil and the Need for Greater Public Health Awareness of Molecular Testing Gilberto Lopes, Brazil

P1.13 (also presented as PD2.01): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America Are Similar Luis Raez, USA

early stage nsclc (stage i - iii)

P1.14: Energy-Based Instruments for Pulmonary Artery Ligation in Thoracoscopic Major Lung Resection Yoshio Tsunezuka, Japan

P1.15: Comparison of Pulmonary Function after Robotic-Assisted Video-Thoracoscopic Lobectomies vs Segmentectomies Eric Toloza, USA

P1.16: Comparison of Peri-Operative Outcomes after Robotic-Assisted Video-Thoracoscopic Lobectomies versus Segmentectomies Eric Toloza, USA

P1.17: Improved Survival for Stage-2 (N1) Pulmonary Adenocarcinoma and Squamous Cell Carcinoma after Pulmonary Lobectomy Danny Nguyen, USA

P1.18: Long-Term Clinical Outcomes and Safety Profile for Central Lung SBRT for NSCLC Kenneth Merrell, USA

P1.19: Barriers to Deliver Personalized Medicine to Young Patients with Non-Small Cell Lung Cancer in Latin America Liliana Fernandez, Columbia

P1.20: Lung Resection Analysis from Brazilian Society of Thoracic Surgery Database Maria Teresa Ruiz Tsukazan, Brazil

P1.21: Novel PET Parameters as Predictors of Pathologic Response in Patients with Stage IIIA(N2) NSCLC Receiving Trimodality Therapy Andrea Arnett, USA

P1.22: Temporal Survival Improvement for Stage-II (T3N0M0) Lung Adenocarcinoma after Pulmonary Lobectomy Danny Nguyen, USA

advanced nsclc

P1.23: Chemotherapy in Lung Cancer at National Institute of Oncology at Paraguay: A Retrospective Study, 8 Years of Experience Silvia Ayala Leon, Paraguay

P1.24: 1st Line Treatment with Erlotinib in Advanced Non Squamous NSCLC: Our Experience. CCSS, San José Costa Rica Raquel Rojas-Vigott, Costa Rica

Poster Session 1 | Friday, August 26, 2016PRESENTING AUTHOR STAND BY TIME: 10:30 – 11:00 AND 16:00 – 16:30


25

GRAGRAM 7THTH

PO

STE

R S

ES

SIO

N 1

| F

RID

AY

, AU

GU

ST 2

6, 2

016

P1.25: Experience with Erlotinib and Gefitnib in Patients with EGFR Mutation Positive Advanced Lung Cancer Cristiane Martin, Panama

P1.26: A Case of Non Small Cell Lung Cancer EGFR Mutation Exon 18 Positive with Poor Response to Targeted Therapy Cláudia Matos, Portugal

P1.27: A Clinicopathological Study of Resected Pulmonary Pleomorphic Carcinoma Yoshio Tsunezuka, Japan

P1.28: Overall Survival In Patients with Metastatic Lung Adenocarcinoma Treated at Instituto Oncologico Nacional. Panama Mario Guardia, Panama

P1.29: “Real World” Use of Liquid Biopsy in Patients with Lung Adenocarcinoma and Correlation with Tumor Tissue Genetic Profile Edgardo Santos, USA

P1.30: Clinical Efficacy and Tolerability of Bevacizumab in Elderly Patients With Advanced Non-Squamous NSCLC Lilibeth Castillero, Panama

P1.31: Pleural Empyema and Broncho Pleural Fistula after Lung Resection: Analyses of 29 Patients Treated in Our Clinic Fadil Gradica, Albania

P1.32: Primary Lung Cancer Presenting as Pneumothorax Fadil Gradica, Albania

P1.33: Afatinib versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6 Luis Fein, Argentina

P1.34: First-Line Afatinib vs Gefitinib for Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial Santiago Ponce Aix, Spain

P1.35: The Role of Salvage SBRT in Recurrent Lung Cancer after Previous Radiotherapy Beatriz Amendola, USA

P1.36: Non-Small-Cell Lung Cancer and Brain Metastases in Brazil Luiza Weis, Brazil

P1.37: First Line Treatment Outcome for EGFR Mutated Metastatic Non-Small Cell Lung Cancer - A Single Institution 5 Years Experience Shahid Gilani, UK

P1.38: Relationship Between TILs and Neutrophil-Lymphocyte Ratio As A Prognostic Factor In Advanced NSCLC Martin Richardet, Argentina

P1.39: Only Two Rare Metastasis of Lung Adenocarcinoma? Cláudia Matos, Portugal

P1.40: Comparative Study of Chemotherapy Regimens Based on Platinum and Its Different Toxicities in Patients with Advanced NSCLC Martin Richardet, Argentina

P1.41 (also presented as PD2.06): Bayesian Network Meta-Comparison of Maintenance Treatments for Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Gilberto Lopes, Brazil

P1.42 (also presented as PD2.04): Pem/CBP/Bev Followed by Maintenance Pem/Bev in Hispanic Patients with NSCLC: Outcomes According to TS, ERCC1 and VEGF Leonardo Rojas, Columbia

P1.43 (also presented as PD2.05): Radiosurgery, a New Paradigm in Metastatic Non-Small Cell Lung Cancer (NSCLC) to the Brain: An Update Beatriz Amendola, USA

P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients with ALK+ NSCLC Ticiana Leal, USA

P1.45 Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6 Carlos Barrios, Brazil

P1.46: Phase I Study of Nivolumab + nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort Nataliya Trunova, USA

P1.47: ABOUND.sqm QoL by Response: Interim Analysis of Squamous NSCLC Pts Treated with nab-Paclitaxel/Carboplatin Induction Therapy Nataliya Trunova, USA

P1.48: nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung Cancer: Outcomes in Elderly Patients with Squamous Histology Teng Jin Ong, USA

P1.49 (also presented as PD1.05): The Genomics of Young Emergent Lung Cancer Barbara Gitlitz, USA

P1.50: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy Carlos Barrios, Brazil

P1.51: Impact of Regulatory Delays in Drug Approval: Mortality and Morbidity Due to with Lack of

Access to Crizotinib in Brazil Carlos Barrios, Brazil


26

GRAGRAM 7THTH

PO

STE

R S

ES

SIO

N 2

| S

AT

UR

DA

Y, A

UG

UST

27,

20

16

sclc, mesothelioma, thymoma

P2.01: LUME-Meso: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Malignant Pleural Mesothelioma Giorgio Scagliotti, Italy

P2.02: Thymic Malignancies. A Single Institution Series from 2006-2016 Flavio Cabral, Brazil

P2.03: Treatment of Malignant Pleural Mesothelioma beyond First-Line among Hispanics (MeSO-CLICaP) Luis Corrales-Rodriguez, Costa Rica

P2.04: Characteristics and Long Term Outcomes of Advanced Pleural Mesothelioma in Latin America (MeSO-CLICaP) Oscar Arrieta, Mexico

biology and pathogenesis

P2.05: The Synthetic Peptide CIGB-300 Inhibits NF-κB Translocation Affecting the Survival and Chemoresistance of NSCLC Cell Lines Stéfano Cirigliano, Argentina

P2.06: Exosomal miRNA Analysis in Non-Small Cell Lung Cancer: New Liquid Biomarker? Christian Rolfo, Belgium

P2.07: Evaluation of Different Exosomal RNA Isolation Methods in NSCLC Liquid Biopsies Christian Rolfo, Belgium

P2.08: Gene Fusions Detected in Non-Small Cell Lung Carcinoma (NSCLC) and Small Cell Lung Carcinoma (SCLC) David Arguello, USA

P2.09: cMET in NSCLC: Expression, Amplification and Mutations Christian Rolfo, Belgium

P2.10: Clinical and Pathological Characteristics of ALK Positive Lung Cancer Patients. Instituto Oncológico Nacional - Panamá Taysser Sowley D, Panama

pathology

P2.12: Treatment Response in Patients with ALK Immunohistochemistry (IHC) Positive with FISH Negative Manglio Rizzo, Argentina

P2.13: Testing Profiles in NSCLC Biopsy Samples: Multi-Institutional Study in Cordoba NORMA Pilnik, Argentina

P2.14: Lung Cancer as Second Primary Cancer in Two Patients in a Reference Hospital in Latin America: A Case Report Liliana Fernandez Trujillo, Colombia

P2.15: Treatment Outcome of Metastatic Breast Angiosarcoma to the Lung, in a Reference Hospital in Latin America: A Case Report Liliana Fernandez Trujillo, Colombia

P2.16: Atypical Adenomatous Hyperplasia (AAH) in a Patient with a Primary Carcinoid Lung Tumor: Case-Report Liliana Fernandez, Columbia

P2.17: Incidence Of Non-small Cell Lung Cancer Biomarkers in Panama; Demographyc, Clinic and Histopathological Features Ruth Vergara, Panama

P2.18: Rapid On-Site Evaluation (ROSE) Technique: Experience in the Pulmonology Unit of a Reference Hospital in Latin America Liliana Fernandez, Columbia

P2.19 (also presented as PD1.04): Infrequent Staining Patterns in ALK Immunohistochemistry: Correlation with Fish Analysis Paola De La Iglesia, Argentina

bronchoscopy

P2.20: Malignant Obstruction of the Central Airway by an EBV(+) Diffuse Large B-Cell Lymphoma: An Unusual Presentation Liliana Fernandez, Columbia

P2.21: Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Experience in a Reference Hospital in Latin America Liliana Fernandez, Columbia

P2.22: Therapeutic Bronchoscopy in Multimodal Therapy for the Management of Central Airway Obstruction in Latin America Liliana Fernandez, Columbia

Poster Session 2 | Saturday, August 27, 2016PRESENTING AUTHOR STAND BY TIME: 10:30 – 11:00 AND 16:15 – 16:45


27

GRAGRAM 7THTH

PO

STE

R S

ES

SIO

N 2

| S

AT

UR

DA

Y, A

UG

UST

27,

20

16

supportive care and others

P2.23: Effectiveness of Methylnaltrexone Bromide as a Treatment for Opioid-Induced Constipation in NSCLC Patients Ioannis Dimitroulis, Greece

P2.24: Pulmonary-Epithelioid Hemangioendothelioma: A Case Report of Spontaneous Regression Raquel Rojas-Vigott, Costa Rica

P2.26: Reference to Palliative Care in Patients with Advanced Lung Cancer Treated with Systemic Therapy. Ion, Panamá Joel Moreno-Ríos, Panama

P2.27: Blood Supplement Research of the Percutaneous Inoculated Canine Transmissible Venereal Tumor Lung Cancer Model Xiao An, China

P2.28: Image-Guided Radiofrecuency Ablation of Lung Metastases. A Single Cancer Center Experience in Panama Jose Pinto Llerena, Panama

P2.29: An Approach to Ensure Adequate Intake of Nutrients for Patients with Lung Cancer Julissa Luvian-Morales, Mexico

P2.31: Understanding Factors Influencing Self-Referral of Patients from Resource-Limited Institutions Seeking Lung Cancer Care Jorge Rios, USA

immunotherapy

P2.32: Survival Assessment of Non-Small Cell Lung Neoplasia Patients in Advanced Stage Treated with the CIMAvax-EGF Vaccine Carlos Cobian, Columbia

P2.33: Safety Profile of Nivolumab Administered as 30-Minute (Min) Infusion: Analysis of Data from CheckMate 153 Eduardo Richardet, Argentina

P2.34: Vaxira and CIMAvax-EGF Therapeutic Vaccines Combination in the Advanced NSCLC Treatment Amparo Macias, Cuba

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis Clarissa Mathias, Brazil

P2.36: Nivolumab (nivo) in Patients (pts) with Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (Mets) Gilberto Lopes, Brazil

P2.37: A Case of Immune-Mediated Pneumonitis? Cláudia Matos, Portugal

P2.38: Nivolumab in Clinical Practice: Real World Experience in an Argentina Oncologic Center Manglio Rizzo, Argentina

P2.39: Long-Term OS for Patients with Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab Suresh Ramalingam, USA

P2.40: CIMAvaxEGF Vaccine for the Treatment of Real-World NSCLC Patients. Maurenis Hernandez, Cuba

P2.41: (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment Roy Herbst, USA

P2.42: An Immunotherapy Approach to Overcoming Resistance to Second and Third Generation EGFR Inhibitors Yosef Yarden, Israel

P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894) Gilberto De Lima Lopes, Brazil

P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a Biomarker Gilberto Lopes, Brazil

P2.45: An Estimate of the Economic Impact of Treatment of NSCLC with Immunotherapy Relative to PD-L1 Expression in Brazil Gilberto Lopes, Brazil

P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit with Nivolumab vs Docetaxel in Pts with Advanced Non-Squamous NSCLC from CheckMate 057 Clarissa Mathias, Brazil

P2.47 (also presented as PD1.02): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis Gilberto Lopes, Brazil


28

GRAGRAM 7THTH

Time Zone

Panama is in the Eastern Standard Time Zone. The time difference is:

UTC/GMT 4 HOURS

CENTRAL EUROPE (IE. LONDON) 5 HOURS

EST (IE. NEW YORK) SAME TIME ZONE

PST (IE. SAN FRANCISCO) -3 HOURS

Electric Power

Electrical plugs are the same as in the USA.

STANDARD VOLTAGE: 120 V

STANDARD FREQUENCY: 60 HZ

POWER SOCKETS: TYPE A / B

Banks

Most bank branches are open Mondays through Fridays from 9:00 – 18:00. Some banks are also open on Saturday morning. Most banks accept the major credit cards.

Currency

Panama uses the US dollar as its currency. The official name for it is the Balboa, but it’s exactly the same bill. Panamanian coins are of the same value, size and metal as US coins.

Taxi

24 hr services at taxi stations, available nationwide at a pre-established cost per route. Taxis in Panama City along the main avenues of Vía España, Transístmica, Tumba Muerto and Avenida Balboa can cost approximately B/.2.00 to B/.3.00 balboas, with fares varying up to an additional B/.1.00. An added fee of approximately $0.25 to $0.50 cents is charged per additional passenger.

Tipping

In Panama, tipping is not compulsory, but is good etiquette and supplements the low wages of the employee. If you’re happy with your service, it is standard to leave a 10% gratuity.

Language

The main and official Panama language is Spanish. However apart from Spanish, another popular Panama language is English, which is fluently spoken by around 14% of the population.

Emergency and Safety

To ensure the comfort and safety of all guests, Panama grants all visitors free medical emergency insurance for 30 days from entry.

San Fernando Hospital Clinic – Vía España, Panama City

Paitilla Medical Center – Ave. Balboa and 53rd Street

PAN

AM

A C

ITY

, PA

NA

MA

Panama City, Panama


29

GRAGRAM 7THTH

For more information and full

descriptions of the tours, please

visit the Conference website

at http://lalca2016.iaslc.org/

networking-events-tours/tours/

LALCA 2016 has partnered with IVI DMC2 Costa Rica & Panama & Colombia, a local tour specialist to provide delegates with the opportunities to explore Panama City and surroundings.

To book a tour, please contact:

Ligia Vargas

Regional Manager DirectorIVI DMC2 Costa Rica & Panama & Colombia

Email: [email protected]

Address: 45th Street, Bella Vista 8th Building – #1 Panama, Panama

Switchboard: (507) 394 5940, (507) 394 5941

Cell Phone: (507) 6560 9886 (within the US and Canada)

WhatsApp: (507) 6560 9886

Skype: ligia_vargas1

Miraflores Locks – Panama Canal

Cultural and Modern Shopping Tour

Biodiversity Museum Tour

Gamboa Rain Forest – Aerial Tram & Ecological Gardens Exhibition

Gatun Lake Boat Tour & Ecological Gardens

Canal Expansion & Gatun Locks

Panama City Tour

TO

UR

S

Tours

APPROX. 4 HOURS

PRICE PER PERSON: 50 USD

APPROX. 4 HOURS


APPROX. 5 HOURS


APPROX. 4 HOURS


APPROX. 4 HOURS


APPROX. 4 HOURS


APPROX. 5 HOURS



30

GRAGRAM 7THTH

AB

STR

AC

T A

UT

HO

R IN

DE

X

A

Aanur, Nivedita ..............................................P2.33

Acosta, Luciana ....................... P1.09, P1.38, P1.40

Acosta Brooks, Soraida C. ............................P2.32

Addario, Bonnie ...............................PD1.05, P1.49

Aggarwal, Charu ............................................P2.39

Agrawal, Shruti ..............................................P2.33

Aguiar Jr, Pedro ..................... O.03, P2.44, P2.45,

............................................................ PD1.02, P2.47

Agusti, Alvar ................................................... P1.03

Agüero Pino, Miguel ........................... P1.02, P1.23

Ahmati, Donika ............................................... P1.31

Ahn, Myung-Ju .................... P2.39, P2.41, PD1.06

Alma, Cani ........................................................ P1.31

Alonso, Maribel .............................................P2.40

Amador, Rosa M. ...........................................P2.40

Amendola, Beatriz ..............P1.35, PD2.05, P1.43

Amendola, Marco A. .......................................P1.35

Amiri, Katayoun I. ..........................................P1.47

Amos, Christopher I. .................................... P1.04

An, Xiao ..........................................................P2.27

Antillón, Sofía ..................................................P1.10

Antonia, Scott ................................................P2.35

Arauz, Erik ................................ P1.25, P2.10, P2.26

Araya, Mónica ..................................................P1.10

Archila, Pilar ......................................................O.01

Argjiri, Dhimitraq ............................................P1.32

Argjri, Dhimitraq ............................................. P1.31

Arguello, David ........................P2.08, O.04, P2.11

Arnett, Andrea L. ........................................... P1.21

Arrieta, Oscar ..........................O.01, P1.05, P2.03,

...................................P2.04, P2.29, PD2.04, P1.42

Avancha, Kiran ................................................O.03

Ayala Leon, Miguel ............................. P1.02, P1.23

Ayala Leon, Silvia J. ...........................P1.02, P1.23

Azevedo, Sérgio ............................................. P1.36

B

B. Blankstein, Kenneth .................................P2.33

Baas, Paul ..........................................P2.41, PD1.06

Babiker, Hani ........................................O.03, P2.45

Bacon, Ludwing .....................P1.05, P2.03, P2.04

Bal De Kier Joffé, Elisa ................................. P2.05

Balmanoukian, Ani S. ....................................P2.39

Banks, Kimberly C. .........................................O.02

Baptista, Joao .................................................P1.10

Barlesi, Fabrice ...............................................P2.35

Barreto, Carmelia .................. O.03, P2.44, P2.45,

............................................................ PD1.02, P2.47

Christiani, David C. ........................................P1.04

Chudova, Darya I. ...........................................O.02

Cimarosti, Maicon J. ..................................... P2.02

Cirigliano, Stéfano ........................................P2.05

Cobian, Carlos O. .......................................... P2.32

Coelho, José P. .........................P1.26, P1.39, P2.37

Coelho, Juliano C. .......................................... P1.36

Corrales-Rodriguez, Luis ..................O.01, P1.05,

........................P1.10, P2.03, P2.04, PD2.04, P1.42

Coy, Sammie .................................... PD2.05, P1.43

Creelan, Ben ....................................................P2.33

Crino, Lucio ......................................... P2.35, P2.36

Crombet, Tania..................................P2.34, P2.40

Cruz, Aivin ......................................................P2.40

Cuello, Mauricio ...................... O.01, P1.05, P2.03,

............................................... P2.04, PD2.04, P1.42

Cárdenas Sánchez, Jesús ............................. P1.50

D

Dalurzo, Liliana .................................PD1.04, P2.19

Dastani, Homa ..................................PD1.01, P2.46

De Castro Jr, Gilberto .....................P2.41, PD1.06

De La Colina, Marcelo ....................................P2.13

De La Iglesia, Paola X. ....................PD1.04, P2.19

De La Torre-Vallejo, Martha ....................... P2.29

De Lima Lopes, Gilberto ..............................P2.43

De Mello, Ramon ............................... O.03, P2.44,

................................................ P2.45, PD1.02, P2.47

De Oliveira, Humberto A. .............................P1.20

De Oliveira Brandao, Cisio ............................ P1.50

Debiasi, Marcio .....................................P1.08, P1.51

Derosa, Michael ............................ PD1.01, PP2.46

Desai, Kaushal ................................................P2.35

Diaz, Pilar ..........................................................P2.13

Dicalbo, Luciano .................................P1.09, P1.38

Dimitroulis, Ioannis A. .................................P2.23

Dolled-Filhart, Marisa ....................P2.41, PD1.06

Dong, Weihua .................................................P2.27

Dubos Arvis, Catherine ..................P2.41, PD1.06

Dukart, Gary ....................................PD2.02, P1.44

Díaz Bessone, María I. .................................. P2.05

E

E Gerber, David ...............................................P2.36

E Vokes, Everett .............................................P2.36

Echavarria, Maria F. ...............................P1.15, P1.16

Barrios, Carlos H.............P1.33, P1.50, P1.51,P1.45

Bellido, Doris ...................................................P1.07

Bello, Loisel ....................................................P2.40

Bender, Ryan......................................... O.04, P2.11

Bengio, Veronica .............................................P2.13

Bennett, Bryan .................................PD1.01, P2.46

Berardi, Damián............................................. P2.05

Bittoni, Marisa ..................................PD1.05, P1.49

Blackwood-Chirchir, Anne ..........................P2.36

Blais, Normand ...............................................P1.05

Blanco, Jesus M. ..............................................P1.35

Blumenschein, George ..................PD2.02, P1.44

Bonet, Mariano ................................................P1.11

Borghaei, Hossein ..........................................P2.35

Bosse, Yohan ..................................................P1.04

Boyer, Michael ................................................ P1.34

Brahmer, Julie ..................................... P2.35, P2.36

Brenes, Alejandro ...........................................P1.10

Brennan, Paul B. .............................................P1.04

C

Caballero, Manuel ...........................................P1.10

Cabral, Flavio L. .............................................P2.02

Cabreja, Angela .............................................. P1.25

Cala, Mireisy ..................................................P2.40

Cam, Caner .................................................... P2.05

Camacho, Kirenia ..........................................P2.40

Camargo, Spencer M. ....................................P1.20

Campos, Christian ..........................................P1.10

Cani, Alma ........................................................P1.32

Canigiani, Maximiliano ..................................P2.13

Carcereny, Enric .............................................P2.39

Cardona, Andrés F. ................. O.01, P1.05, P2.03,

............................................... P2.04, PD2.04, P1.42

Carranza, Hernán ................................O.01, P2.03,

............................................... P2.04, PD2.04, P1.42

Carter, Corey ...................................PD2.02, P1.44

Castiglia, Marta .............................................P2.06

Castillero, Lilibeth ............................ P1.29, P1.30,

.............................................................. PD2.01, P1.13

Castillo-Fernandez, Omar O. ......... P1.05, P1.07,

...............................................................P1.28, P2.28

Cepeda, Meylan ............................................P2.40

Chacon, Reinaldo ................................P2.12, P2.38

Chacón, Matías ..............................................P2.38

Chandler, Jason..............................................P2.33

Chen, Ruthia .....................................PD1.05, P1.49

Chen, Tianlei ...................................................P1.48

Cheng, Anna ..........................................P1.15, P1.16

Chirinos, Luis .....................................P2.03, P2.04

Abstract Author IndexPRESENTATIONS HIGHLIGHTED IN BOLD = PRESENTING AUTHOR FOR THIS ABSTRACT


31

GRAGRAM 7THTH

AB

STR

AC

T A

UT

HO

R IN

DE

X

J

J Geese, William .............................................P2.36

J. Gralla, Richard ..............................PD1.01, P2.46

J. Mccleod, Michael .......................................P2.33

Jegannathen, Apurna ....................................P1.37

Jennings, Mark .................................PD1.05, P1.49

Jiménez, Ernesto ............................................P1.10

Johnson, Melissa ...........................................P1.47

Jotte, Robert ..................................................P1.47

Juárez, Melissa .....................................P1.05, P1.10

K

K Dy, Grace ......................................................P2.36

Kapisyzi, Perlat ................................................ P1.31

Karagoz, Bulent................................. P2.05, P2.12

Kato, Terufumi ................................................P1.33

Keenan, Robert J. ................................ P1.17, P1.22

Kelly, Karen .....................................................P1.46

Kim, Alice Y. ....................................... PD2.01, P1.13

Kim, Dong-Wan ...............................P2.41, PD1.06

Kim, Joo-Hang .................................P2.41, PD1.06

Kimbrough, Jeff ............................................P2.08

Kiura, Katsuyuki .............................................P1.33

Kkloecker, Goetz H. .......................................P2.31

Knoble, Jeanna ..............................................P1.47

Ko, Amy ....................................P1.46, P1.47, P1.48

Kohlhaeufl, Martin ........................................P2.36

Kokici, Fahri ..................................................... P1.31

Kush, Debra ................................................... P2.43

L

Labanca, Maria J. .............................PD1.04, P2.19

Lala, Donika .....................................................P1.32

Landi, Maria T. ................................................P1.04

Langer, Corey .................................................P1.47

Lanman, Richard .............................................O.02

Lauricella, Leticia ...........................................P1.20

Leal, Ticiana ................................... PD2.02, P1.44

Lee, Christine E. ..............................................O.02

Lee, Ki Hyeong ................................................P1.33

Leguina, Laura ................................................ P2.12

Leighl, Natasha ..............................................P2.39

Leon, Liliana .................................................... P2.18

Li, Ang .......................................P2.33, P2.35, P2.36

Liang, Chris ......................................PD2.02, P1.44

Liapikou, Adamantia .....................................P2.23

Liedke, Pedro .................................................. P1.36

Lim, Maria .............................................P1.07, P1.28

Lisha, Lutfi .............................................P1.31, P1.32

Lopes, Gilberto ............ O.03, P1.08,P1.51, P2.36,

................................ P2.44, P2.45, PD1.02, P2.47,

Gockerman, Jon ..............................PD2.02, P1.44

Gomez, Roberto............................................ P2.34

Gonzalez, Matilde .........................................P2.40

Gonzalez-Ling, Ana ..................................... P2.29

González, Ileana ..............................................P1.10

González, Lisde .................................P2.03, P2.04

Gorur, Rauf ..................................................... P2.05

Gradica, Fadil ........................................P1.31, P1.32

Gradica, Flora ........................................P1.31, P1.32

Gradica, Sali ...........................................P1.31, P1.32

Gridelli, Cesare ...............................................P1.48

Guadamuz, Randall ........................................P1.10

Guardia, Mario ............................................... P1.28

Gubens, Matthew ..........................................P2.39

Guedes Pinto, Erique ....................................P1.06

Guerra, Pedro P. .............................................P2.40

Gutierres, Barbara ..............................O.03, P2.45

Gutiérrez, Leidys ......................P1.19, P2.16, P2.18,

....................................................P2.20, P2.21, P2.22

H

Hallemeier, Christopher L. ............................P1.18

Han, Ji-Youn .....................................P2.41, PD1.06

Harrow, Kimberly ............................PD2.02, P1.44

Havel, Libor .....................................................P2.36

Healey, Diane ...................................... P2.35, P2.36

Heck, Jayme R. .............................................. P2.02

Hellmann, Matthew .......................... P2.35, P2.39

Henao, Juan F. .................................................P1.19

Henry, David H. .............................................. P1.50

Herbst, Roy S. ................................................ P2.41

Hernandez, Maurenis ................... P2.40, PD1.06

Hernandez, Patricia A. ........... P1.09, P1.38, P1.40

Hirsh, Vera ...................... P1.33, P1.34, P1.47, P1.45

Hochhegger, Bruno .......................................P1.06

Holgado, Esther .............................................P2.36

Horn, Leora ........................................ P2.33, P2.35,

................................................ P2.39, PD2.02, P1.44

Hu, Cheng-Ping .............................................P1.45

Hui, Rina ..........................................................P2.39

Hung, Rayjean ................................................P1.04

Hunis, Brian ............................. P1.29, PD2.01, P1.13

I

Im, Ellie ..............................................P2.41, PD1.06

Infante, Jeffrey ...............................PD2.02, P1.44

Irion, Klaus ......................................................P1.06

Isitmangil, Turgut ......................................... P2.05

Eder, Joseph P. ................................................P2.39

Ellis, Phil ..........................................................P2.08

Eltoukhy, Helmy..............................................O.02

Ernst Erich Eberhardt, Wilfried ...................P2.35

Escobar, Juliana ............................................. P2.18

Ezequiel Neto, Wilson.................................. P1.06

F

Farina, Hernán ............................................... P2.05

Fayette, Jérome .............................................P2.35

Fein, Luis..........................................................P1.33

Felip, Enriqueta .........P2.35, P2.39, P2.41, PD1.06

Felizardo, Margarida................P1.26, P1.39, P2.37

Feria, Francisco M. .........................................P2.32

Fernandez, Liliana..............................P1.19, P2.16,

...................................... P2.18, P2.20, P2.21, P2.22

Fernandez Trujillo, Liliana ................P2.14, P2.15

Fidler, Mary Jo ..................................P2.41, PD1.06

Field, John K. ..................................................P1.04

Figueiredo Pinto, José Antônio ................. P2.02

Fleishman, Alex .............................................. P1.50

Flumian, Carolina .......................................... P2.05

Fonseca, Vivian .............................................P2.40

Fontaine, Jacques-Pierre ..................P1.15, P1.16,

................................................................. P1.17, P1.22

Fortunato, Gustavo .......................................P1.20

Furtado, Sofia T. .......................P1.26, P1.39, P2.37

G

Gaafar, Rabab .................................................P2.01

Gandara, David R. .......................................... O.02

Gandhi, Leena ................................................P2.39

Garassino, Marina ..........................................P2.36

Garces, Yolanda I. .................................P1.18, P1.21

Garcia, Elena .................................................. P2.34

Garcia, Ivon ....................................................P2.40

Garcia, Lina M. ................................................ P2.16

Garon, Edward B. ................. P2.39, P2.41, PD1.06

Garrett, Joseph .....................................P1.15, P1.16

Garrido, Marcelo ............................................P2.41

Gascón, Pere ................................................... P1.50

Gatalica, Zoran ......................... O.04, P2.08, P2.11

Gauna Colás, Cinthia .......................... P1.02, P1.23

Geater, Sarayut L. ............................... P1.33, P1.45

Geib, Guilherme ............................................. P1.36

George, Ben ....................................................P1.46

Gettinger, Scott .............................................P2.36

Giallombardo, Marco........................ P2.06, P2.07

Gibbons, James ...............................PD2.02, P1.44

Gilani, Shahid ..................................................P1.37

Giovannetti, Elisa .........................................P2.09

Giridharan, S ....................................................P1.37

Gitlitz, Barbara ............................... PD1.05, P1.49


32

GRAGRAM 7THTH

AB

STR

AC

T A

UT

HO

R IN

DE

X

.................................. PD1.03, P1.12, PD2.06, P1.41

Lopez, Roberto ..............................................P1.28

Lorenzo, Elba ....................................................P1.11

Lorenzo, Geidy ..............................................P2.40

Losco, Federico ..............................................P2.38

Lovly, Christine ...............................PD2.02, P1.44

Lu, Shun ...........................................................P1.45

Lubiniecki, Gregory M. .................................P2.39

Luvian-Morales, Julissa ..............................P2.29

López, Roberto ................................... P1.07, P1.25

M

M. Waxman, Ian ..............................................P2.33

Macias, Amparo E. ........................................P2.34

Mack, Philip C. .................................................O.02

Majem, Margarita ............................P2.41, PD1.06

Mando, Pablo .......................................P2.12, P2.38

Marana, Camila ..............................................P1.29

Marchiori, Edson ............................................P1.06

Marks, Patrícia ................................................ P1.36

Marrades, Ramon........................................... P1.03

Martin, Claudio ....................... O.01, P1.05, P2.03,

.........................P2.04, P2.12, P2.38, PD2.04, P1.42

Martin, Cristiane .................................P1.25, P2.17

Martinez, William ........................................... P2.18

Mas, Luis ..........................................................P1.05

Mass, Luis ...........................................P2.03, P2.04

Massey, Dan ......................................... P1.33, P1.45

Mathias, Clarissa ...............................P1.08, P2.35,

........................................................... PD1.01, P2.46

Matos, Cláudia P. ....................P1.26, P1.39, P2.37

Mazorra, Zaima ............................................. P2.34

Mccleod, Michael ...........................................P1.47

Mckay, James P. .............................................P1.04

Mekhail, Tarek ................................................P2.33

Mendoza, Ivis .....................................P2.34, P2.40

Merrell, Kenneth W. ............................ P1.18, P1.21

Middleton, Gary W. .......................................P2.39

Mohamed, Mohamed....................................P2.33

Mohammed, Taqee Ansari ........................... P1.01

Mohammed Al Bassir, Rahamani .................P1.01

Mok, Tony ........................................... P1.33, P1.34,

...............................................................P2.43, P1.45

Molina, Julian ...................................P2.41, PD1.06

Molina, Matias ......................... P1.09, P1.38, P1.40

Molina, Rafael .................................................P1.03

Monaghan, Colin............................................P1.06

Monge Castro, Cinthya ...............................P2.24

Monroy Orozco, Karen ....................... P2.14, P2.15

Montano, Lilian ...................................P1.07, P1.28

Moodie, Carla ........................................P1.15, P1.16

Moreno-Ríos, Joel .................. P2.10, P2.17, P2.26

Morsli, Nassim ................................................P2.01

Mortimer, Stefanie A. ....................................O.02

Mou, Benjamin ................................................P1.18

Moura Barrios, Pablo ...................................... P1.51

Mourafetis, Jennifer ........................ PD2.01, P1.13

Murillo, Adriana ...............................................P1.10

Murray, Drew C.D. ...........................................P2.31

Märten, Angela ........................ P1.33, P1.34, P1.45

N

Nagarkar, Rajnish ........................................... P1.50

Nagy, Rebecca J. .............................................O.02

Nelson, Katy ....................................................P1.18

Neninger, Elia ................................................P2.40

Ng, Emily ................................................P1.15, P1.16

Nguyen, Danny T. ............................... P1.17, P1.22

Nikolinakos, Petros .......................................P2.33

Novello, Silvia ...................................PD1.05, P1.49

Nowak, Anna ..................................................P2.01

Nunes Filho, Paulo R. ....................................P1.08

O

O’Brien, Mary ..................................................P1.48

O’Dwyer, Peter ...............................................P1.46

Oblitas, George .................................P2.03, P2.04

Odegaard, Justin ............................................O.02

Oechsli, Malgorzata .......................................P2.31

Okamoto, Isamu ............................................P1.45

Oliveira, Pedro ...............................................P2.44

Olivier, Kenneth R. ..........................................P1.18

Ong, Teng Jin...................................... P1.47, P1.48

Ordoñez, Pablo................................................P1.10

Orlov, Sergey ...................................................P1.33

Orsini, Lucinda .................................PD1.01, P2.46

Ortiz, Carlos ...........................O.01, PD2.04, P1.42

Ortiz, Ramon ................................................. P2.34

Ortiz, Ramon A. .............................................P2.40

Otero, Jorge .........................................O.01, P2.03,

............................................... P2.04, PD2.04, P1.42

Owen, Dawn A. ................................................P1.18

Oxnard, Geoffrey .............................PD1.05, P1.49

O’Byrne, Kenneth .................... P1.33, P1.34, P1.45

P

Packard, Ann T. ...............................................P1.21

Page, Ray .........................................................P1.47

Paradelo, Martin ............................................ P1.38

Park, S. Lani .......................................PD1.05, P1.49

Patnaik, Amita................................................P2.39

Pauwels, Patrick .................... P2.06, P2.07, P2.09

Paz-Ares, Luis ......................................P1.34, P2.35

Penha, Diana ...................................................P1.06

Pere, Alketa......................................................P1.32

Perea, Silvio ................................................... P2.05

Pereira, Maria Rita .............................. P1.02, P1.23

Pereira, Rodrigo ............................................. P1.36

Perez, Naipy C. ................................................P1.35

Perez De La Puente, Constanza .......P2.12, P2.38

Perez-Gracia, Jose L. ......................P2.41, PD1.06

Peters, Godefridus J. ...................................P2.09

Pets, Evelin ...................................................... P1.38

Pilnik, Norma G. .............................................P2.13

Pinkston, Christina .........................................P2.31

Pinto, Darcy R. ................................................P1.20

Pinto Llerena, Jose ...........................P2.26, P2.28

Pinzon, Onica.................................................. P2.17

Piperdi, Bilal ....................................................P2.39

Pluzanski, Adam.............................................P2.36

Ponce Aix, Santiago ......................................P1.34

Popa, Xitlally .................................................. P2.34

Popat, Sanjay ..................................................P2.01

Postmus, Pieter ..............................................P1.48

Powazniak, Yanina ........................................ P2.12

Prado, Edna ........................................ PD1.03, P1.12

Puparelli, Carmen .................... P2.12, P2.12, P2.38

Pérez, María Angelina ......................P2.03, P2.04

Q

Qm Chow, Laura.............................................P2.36

R

R. Penrod, John ................................PD1.01, P2.46

Raez, Luis E. ...........................P1.29, PD2.01, P1.13

Ramalingam, Suresh ....................................P2.39

Ramos Esqueivel, Allan ................................P1.24

Ramos-Esquivel, Allan .......................P1.05, P1.10

Rangwala, Reshma ....................................... P2.43

Ready, Neal .....................................................P2.35

Reck, Martin ......................... P2.35, PD1.01, P2.46

Reckamp, Karen .................. P2.36, PD2.02, P1.44

Reclusa, Pablo ....................... P2.06, P2.07, P2.09

Reguart, Noemi .....................................O.01, P1.03

Rexha, Valbona .....................................P1.31, P1.32

Reynolds, Craig ..............................................P2.33

Richardet, Eduardo............................P1.09, P1.38,

...............................................................P1.40, P2.33

Richardet, Martin ...................P1.09, P1.38, P1.40

Rios, Jayme O. ............................................... P2.02

Rios, Jorge A. ..................................................P2.31

Rivera, Tania ....................................................P1.10

Rizvi, Naiyer ....................................................P2.35

Rizzo, Manglio M. ...............................P2.12, P2.38

Robinson, Lary A.................................. P1.17, P1.22

Rodriguez, Maria C. ......................................P2.40

Rodríguez, Luis ................................................P1.10


33

GRAGRAM 7THTH

AB

STR

AC

T A

UT

HO

R IN

DE

X

Rodríguez, Warner ..........................................P1.10

Rojas, Leonardo ...................... O.01, P1.05, P2.03,

.............................................. P2.04, PD2.04, P1.42

Rojas-Vigott, Raquel .......................P1.24, P2.24

Rolfo, Christian ................... P2.06, P2.07, P2.09

Romero, Lázaro I. ...........................................P2.32

Romero Méndez, Steffi ...............................P2.24

Rosell, Rafael .......................... O.01, P2.03, P2.04,

............................................................PD2.04, P1.42

Rosenthal, Renata M. ................................... P2.02

Ruiz Tsukazan, Maria Teresa ........... P1.20, P2.02

Ruíz, Maylin .................................................... P2.28

S

S Ramalingam, Suresh ..................................P2.36

Sable-Hunt, Alicia ...........................PD1.05, P1.49

Sadowski, Sara .............................................. P2.43

Salanova, Ruben ............................................ P2.12

Salomon, Eva .................................................P2.40

Sampaio, Fernanda H. ...................................P1.08

Sanabria, Fernando ....................................... P2.18

Sanchez, Aura ................................................. P2.21

Sanchez, Carlos .............................................P2.40

Santiesteban, Eduardo ................................ P2.34

Santoro, Ilka ....................................... O.03, P2.44,

............................................................ PD1.02, P2.47

Santos, Edgardo S............................. P1.29, P1.30,

.............................................................. PD2.01, P1.13

Sareli, Candice ................................... PD2.01, P1.13

Saumel, Yaimarelis .......................................P2.40

Scagliotti, Giorgio V. .................................... P2.01

Schmitt, João R............................................. P2.02

Schuler, Martin .................................... P1.33, P1.45

Schwarcke, Gabriel M. ................................. P2.02

Schwartsmann, Gilberto .............................. P1.36

Sebastian, Martin ..........................................P1.45

Selimi, Elez .......................................................P1.32

Sequist, Lecia V. .................................. P1.33, P1.45

Shah, Riyaz ......................................................P1.45

Shentu, Yue ......................................P2.41, PD1.06

Sirera, Rafael.................................................. P2.07

Socinski, Mark ................................................P1.48

Soliman, Hatem .............................................P1.46

Solís, Bruno ......................................................P1.10

Sorber, Laure .................................................P2.06

Soria, Jean-Charles .......................................P2.39

Soto, Tatiana....................................................P1.10

Sowley D, Taysser ................... P2.10, P2.17, P2.26

Spigel, David ............................P1.47, P2.33, P2.35,

................................................. P2.36, PD1.01, P2.46

Stamou, Panagiota ........................................P2.23

Steins, Martin .................................................P2.35

Sua, Luz F. ..................................P1.19, P2.14, P2.15,

..............................P2.16, P2.18, P2.20, P2.21, P2.22

Sun, Zhichao ...................................................P2.27

Surmont, Veerle ...............................P2.41, PD1.06

Suñé, Karen .................................................... P2.26

Swensen, Jeff ................................................P2.08

Syrigos, Kostas ............................................... P1.50

T

Tadokoro, Hakaru ............................. O.03, P2.44,

................................................ P2.45, PD1.02, P2.47

Talasaz, Amirali ...............................................O.02

Tan, Eng-Huat ................................................ P1.34

Tapia, Héctor ................................................. P2.28

Taylor, Fiona .....................................PD1.01, P2.46

Teixeira, Encarnação .....................................P2.37

Terra, Ricardo M. ............................................P1.20

Todaro, Laura ................................................. P2.05

Toloza, Eric ............................................P1.15, P1.16

Toloza, Eric M. ...................................... P1.17, P1.22

Torres, Lourdes T. .........................................P2.40

Toumbis, Michail ............................................P2.23

Trunova, Nataliya ............................. P1.46, P1.47

Tsai, Chun-Ming .............................................P1.33

Tsunezuka, Yoshio ..............................P1.14, P1.27

U

Urtreger, Alejandro ...................................... P2.05

V

Valdes, Rolando ............................................P2.40

Valentino, Anna ............................................ P2.07

Valladares, René .............................................P1.10

Van Der Laat, Alicia .......................................P1.24

Van Der Steen, Nele .........................P2.06, P2.09

Vanpittius, G ....................................................P1.37

Vargas, Carlos ......................................O.01, P2.03,

............................................... P2.04, PD2.04, P1.42

Varona Perez, Patricia .................................... P1.11

Vavala, Tiziana .................................PD1.05, P1.49

Velasquez, Mauricio ..........................P2.16, P2.18,

............................................................... P2.21, P2.22

Velema, Derek ................................................P2.01

Velez, Frank ...........................................P1.15, P1.16

Velis, Evelio ........................................ PD2.01, P1.13

Vengalil, S .........................................................P1.37

Vergara, Ruth.......................................P2.10, P2.17

Viada, Carmen ...............................................P2.40

Villalobos, Manuel ..........................................P1.10

Villavicencio, Rocio ............................P1.09, P1.38

Vogelzang, Nicholas J...................................P2.01

Volio, Andrés ...................................................P1.10

Von Wangenheim, Ute .................................P2.01

Voss, Andreas ........................... O.04, P2.08, P2.11

W

W. Goldman, Jonathan .................................P2.36

Wainberg, Zev ................................................P1.46

Wakelee, Heather ...........................PD2.02, P1.44

Waqar, Saiama .................................PD2.02, P1.44

Waterhouse, David ............................ P1.46, P2.33

Weis, Luiza N. .................................................P1.36

Werutsky, Gustavo ........................................P1.08

West, Howard J. .............................................P1.47

Wills, Beatriz ........................................O.01, P2.03,

............................................... P2.04, PD2.04, P1.42

Wind, Sven ......................................................P1.45

Wolf, Azik ......................................... PD2.05, P1.43

Wu, Xiaodong ..................................................P1.35

Wu, Yi-Long ............................ P1.33, P2.43, P1.45

X

Xx, Xx ...............................................................P2.35

Y

Yamamoto, Nobuyuki ....................... P1.33, P1.45

Yang, James Chih-Hsin .......... P1.33, P1.34, P1.45

Yarden, Yosef ................................................P2.42

Z

Zaffaroni, Facundo ........................................P1.08

Zapata, Martín I. ...............................................O.01

Zayas, Anet .................................................... P2.34

Zeledón, Zenén ...............................................P1.10

Zhang, Jin ............................................P2.39, P2.43

Zhang, Li ...............................................P1.34, P1.50

Zill, Oliver A. .....................................................O.02

Zukin, Mauro ..................................................P1.08

Zuñiga, Valeria ................................................P1.19

Zúñiga, Carlos .................................................P1.10

Šmakal, Martin ............................................... P1.50

Co

pyr

ight

©20

16 B

oeh

ring

er In

gel

heim

Inte

rnat

iona

l Gm

bH

. All

rig

hts

are

rese

rved

. Pro

ced

ure

ID :

4931

– A

ugus

t 20

16.

Superior efficacy vs gefitiniband vs chemotherapydemonstrated in 3 large trialsin 1st-line EGFR M+ NSCLC*1-4

GIOTRIF ®

* LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin): superior PFS (primary endpoint) and superior OS in Del19 subgroup (secondary endpoint); LUX-Lung 7 (vs gefitinib): superior PFS (co-primary endpoint).

Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the US under the brand name GILOTRIF®. In Europe it is approved for use in patients with distinct types of EGFR mutation-positive NSCLC and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications.

EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer; PFS=progression-free survival; OS=overall survival; SqCC=squamous cell carcinoma; TTF=time to treatment failure.

1. Yang JC et al. Lancet Oncol. 2015;16(2):141-51.2. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.3. Wu YL et al. Lancet Oncol. 2014;15(2):213-22.4. Park K et al. Lancet Oncol. 2016;17(5):577-89.

Exclusive material for health professional

20mg 30 mg 40 mg 50 mg

CR 0281-00 0281-00 0281-00 0281-00

CU 0281-04 0281-04 0281-04 0281-04

SV 0281-04 0281-04 0281-04 0281-04

GT 0281-00 0281-00 0281-00 0281-00

HN Not yet approved 0281-00 0281-00 Not yet

approved

PA 0281-00 0281-00 0281-00 0281-00

NI 0281-00 0281-00 0281-00 0281-00

DO 0281-00 0281-00 0281-00 0281-00

5

REGISTER NOW Don’t miss the Early Registration Deadline!

SEPTEMBER 23, 2016

LUNG CANCERWCLC 2016 TOGETHER AGAINST

DECEMBER 4–7, 2016

VIENNA, AUSTRIA

IASLC 17TH WORLD CONFERENCE ON LUNG CANCER

Join us for the IASLC 17th World Conference

on Lung Cancer in Vienna 2016!

BECOME A MEMBER OF IASLC

WWW.IASLC.ORG

FOLLOW US ON TWITTER @IASLC #WCLC2016

FOLLOW US ON FACEBOOK

Save the Date

SSSSECOMING

UP SOON!

6

WWW.IASLC.ORG

Find us on facebook.com/IASLC/

Follow us @IASLC

LALCA 2018 /

Join us inCordoba, Argentinafor the 8th Latin AmericanConference on Lung Cancer!

FINAL SCIENTIFIC PROGRAM -...

Documents

Transcript of FINAL SCIENTIFIC PROGRAM -...